Abstract 27P
Background
With the development of immune checkpoint inhibitors (ICI), microsatellite instability (MSI) has become an important biomarker. While large multigene hybrid capture next-generation sequencing (NGS) panels are highly accurate in detecting MSI, the sensitivity of small amplicon-based panels is unknown.
Methods
Next-generation sequencing (NGS) was performed on FFPE samples from patients with any stage colorectal cancer (CRC) using the Solo Atlas Pro amplicon panel covering 38 genes and 39 mononucleotide short tandem repeats for MSI analysis. 5-loci polymerase chain reaction (PCR)-based MSI analysis was used as a reference method. MSI by NGS was estimated based on the distribution of k-mers. Statistical analysis was performed using Cohen’s kappa (к), Mann Whitney and Fisher’s exact test.
Results
A total of 160 samples were analyzed using NGS and PCR. Median coverage was 2352x (range, 238-28447х), MAPD – 0.368 (range, 0.236-0.731). Based on PCR results, 42 (46.25%) samples were MSI, 118 (73.75%) – MSS. Based on NGS results, 40 (25%) samples were MSI, 120 (75%) were MSS. NGS and PCR were concordant in 98.75% (158/160) of samples (к=0.97). Sensitivity of NGS was 95.24% (95% CI, 83.84%-99.42%), specificity – 100.00% (96.92%-100.00%), accuracy – 98.75% (95.56%-99.85%). All NGS false positives cases had suboptimal FFPE quality, suggested by absence of any somatic mutations identified. MSI samples had a significantly higher amount of somatic mutations than MSS samples (median, 3 vs 1, p<0.0001). In silico mixing of the sequencing data of 11 MSI samples demonstrated that the minimal sample fraction with the detectable MSI was 0.5%; at 2.5% MSI was detectable in all samples.
Conclusions
The Atlas Pro amplicon panel demonstrates high concordance with PCR and is highly sensitive in detecting MSI in CRC samples.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
142P - Lipidomic signature in response to omega-3 fatty acids and γ-linolenic acid supplementation in breast cancer patients receiving aromatase inhibitors
Presenter: Vesna Vucic
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
Presenter: Simone Rota
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Is it time to incorporate next generation sequencing of body fluids for detection of circulating tumor DNA (ctDNA) alterations?
Presenter: Aditya Shreenivas
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Unveiling the molecular landscape of head and neck cancer: Pathway dysregulations and potential therapeutic targets
Presenter: Rajeev Vijayakumar
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - ESR1 fusions as potential mechanism of resistance to endocrine therapy in metastatic breast cancer
Presenter: Sewanti Limaye
Session: Cocktail & Poster Display session
Resources:
Abstract
147P - Clinical characteristics and outcomes in non-small cell lung cancer patients harboring rare mutations: A single center real-world data
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Diversity of genomic mechanisms of resistance to endocrine therapy in ER+ breast cancer
Presenter: Prithika Sritharan
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Assessing treatment options for gynaecological cancers (GC) using next-generation sequencing (NGS): A real-world analysis
Presenter: Álvaro García
Session: Cocktail & Poster Display session
Resources:
Abstract
150P - Prevalence of DPYD variants in 1478 cancer patients receiving fluoropyrimidine chemotherapy: A real-world data analysis
Presenter: Bahaaeldin Baraka
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Unravelling the limitations of next-generation sequencing (NGS)-based liquid biopsy (LB) across solid tumors: The PREICO-LB project
Presenter: Cinta Hierro
Session: Cocktail & Poster Display session
Resources:
Abstract